Homa Yeganegi
Directeur Technique/Scientifique/R&D chez AGENUS INC.
Postes actifs de Homa Yeganegi
Sociétés | Poste | Début | Fin |
---|---|---|---|
AGENUS INC. | Directeur Technique/Scientifique/R&D | 20/07/2023 | - |
Historique de carrière de Homa Yeganegi
Anciens postes connus de Homa Yeganegi
Sociétés | Poste | Début | Fin |
---|---|---|---|
TURG POIN | Corporate Officer/Principal | 06/01/2020 | - |
CLOVIS ONCOLOGY, INC. | Corporate Officer/Principal | - | - |
HALOZYME THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/03/2016 | - |
Corporate Officer/Principal | - | - |
Formation de Homa Yeganegi
University of Tehran | Undergraduate Degree |
The University of Western Australia | Graduate Degree |
Statistiques
Internationale
Etats-Unis | 5 |
Iran | 2 |
Australie | 2 |
Opérationnelle
Corporate Officer/Principal | 3 |
Chief Tech/Sci/R&D Officer | 2 |
Undergraduate Degree | 1 |
Sectorielle
Health Technology | 5 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
HALOZYME THERAPEUTICS, INC. | Health Technology |
AGENUS INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Turning Point Therapeutics, Inc.
Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Clovis Oncology, Inc.
Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |
- Bourse
- Insiders
- Homa Yeganegi
- Expérience